Display options
Cite
Plotkin SA. The Value of Human Challenges in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development. Clin Infect Dis. 2021;72(4):716-717doi: 10.1093/cid/ciaa1013.
Plotkin, S. A. (2021). The Value of Human Challenges in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 72(4), 716-717. https://doi.org/10.1093/cid/ciaa1013
Plotkin, Stanley A. "The Value of Human Challenges in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 72,4 (2021): 716-717. doi: https://doi.org/10.1093/cid/ciaa1013
Plotkin SA. The Value of Human Challenges in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development. Clin Infect Dis. 2021 Feb 16;72(4):716-717. doi: 10.1093/cid/ciaa1013. PMID: 32674139; PMCID: PMC7543275.
Copy Download .nbib Format: NLM
Share it on

Clin Infect Dis. 2021 Feb 16;72(4):716-717. doi: 10.1093/cid/ciaa1013.

The Value of Human Challenges in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Stanley A Plotkin

Affiliations

  1. Pediatrics, University of Pennsylvania, Vaxconsult, Doylestown, Pennsylvania, USA.
  2. Sanofi Pasteur, Doylestown, Pennsylvania, USA.

PMID: 32674139 PMCID: PMC7543275 DOI: 10.1093/cid/ciaa1013

[No abstract available.]

Substances

MeSH terms

Publication Types